New immunotherapy drug in cancer

New immunotherapy drugs in cancer treatment
Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from cancer with the molecule M7824. These researchers are also undertaking trials with those suffering from pancreatic cancer and those infected with HPV.

Share This Post

Immune checkpoint inhibitors are a class of drugs that fight with the immune system of the body to fight cancerous cells. However, most patients do not respond to these therapies. There is a newer class of drug that targets two proteins involved in suppressing the body’s immune response against tumors.

Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from cancer with the molecule M7824. These researchers are also undertaking trials with those suffering from pancreatic cancer and those infected with HPV.

There are many other trials and experiments being taken to treat and cure cancer more effectively in different research institutes. This drug with a dual approach will be a boon in the treatment of cancer, as with a single molecule, multiple therapies are included.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy